Michihiro Mutoh Selected Research

Adipokines

10/2018	Fatty pancreas: A possible risk factor for pancreatic cancer in animals and humans.
3/2013	Involvement of inflammatory factors in pancreatic carcinogenesis and preventive effects of anti-inflammatory agents.
1/2012	Suppressive effect of pioglitazone, a PPAR gamma ligand, on azoxymethane-induced colon aberrant crypt foci in KK-Ay mice.
11/2011	Enhancement of carcinogenesis and fatty infiltration in the pancreas in N-nitrosobis(2-oxopropyl)amine-treated hamsters by high-fat diet.
6/2011	Loss of adiponectin promotes intestinal carcinogenesis in Min and wild-type mice.
3/2011	Inhibition of intestinal polyp formation by pitavastatin, a HMG-CoA reductase inhibitor.
4/2008	Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polyp formation in Min mice.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michihiro Mutoh Research Topics

Disease

71	Neoplasms (Cancer) 12/2023 - 01/2002
50	Carcinogenesis 12/2023 - 01/2002
43	Colorectal Neoplasms (Colorectal Cancer) 02/2023 - 03/2006
25	Intestinal Polyps 03/2022 - 02/2005
24	Polyps 01/2023 - 03/2006
24	Colonic Neoplasms (Colon Cancer) 03/2022 - 01/2002
16	Adenocarcinoma 01/2022 - 05/2005
15	Pancreatic Neoplasms (Pancreatic Cancer) 01/2022 - 08/2007
13	Adenomatous Polyposis Coli (Familial Adenomatous Polyposis) 11/2023 - 04/2008
12	Adenoma (Adenomas) 01/2023 - 12/2006
9	Inflammation (Inflammations) 12/2023 - 01/2006
8	Aberrant Crypt Foci 01/2023 - 01/2002
8	Hyperlipidemias (Hyperlipidemia) 03/2013 - 02/2005
6	Body Weight (Weight, Body) 07/2021 - 10/2006
5	Obesity 07/2021 - 08/2011
3	Carcinoma (Carcinomatosis) 10/2006 - 04/2002
2	Prostatic Neoplasms (Prostate Cancer) 12/2023 - 10/2023
2	Hypoxia (Hypoxemia) 01/2019 - 01/2018
2	Lung Neoplasms (Lung Cancer) 01/2017 - 08/2015
2	Hypertriglyceridemia 01/2016 - 04/2008
2	Hyperplasia 08/2013 - 08/2008
2	Type 2 Diabetes Mellitus (MODY) 07/2013 - 10/2007

Drug/Important Bio-Agent (IBA)

20	Messenger RNA (mRNA)IBA 04/2020 - 01/2002
17	AzoxymethaneIBA 01/2023 - 01/2002
17	fucoxanthinIBA 01/2022 - 07/2017
13	Proteins (Proteins, Gene)FDA Link 11/2023 - 04/2002
13	fucoxanthinolIBA 07/2022 - 07/2017
10	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2023 - 02/2013
10	LipidsIBA 07/2017 - 02/2005
9	Triglycerides (Triacylglycerol)IBA 12/2022 - 04/2006
9	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 03/2022 - 01/2002
8	colibactinIBA 02/2023 - 01/2019
8	nitrosobis(2-oxopropyl)amine (NBOP)IBA 05/2021 - 08/2007
7	AdipokinesIBA 10/2018 - 04/2008
6	CateninsIBA 12/2023 - 07/2013
6	Peroxisome Proliferator-Activated Receptors (PPAR)IBA 11/2023 - 02/2005
6	LigandsIBA 01/2023 - 08/2007
6	Carotenoids (Carotene)IBA 07/2022 - 12/2019
6	CarcinogensIBA 01/2019 - 01/2002
6	Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA 11/2015 - 03/2002
5	Glycine (Aminoacetic Acid)FDA LinkGeneric 11/2020 - 01/2018
5	Interleukin-6 (Interleukin 6)IBA 04/2020 - 01/2012
5	ProstaglandinsIBA 03/2014 - 01/2002
4	ChloridesIBA 07/2022 - 01/2005
4	EnzymesIBA 01/2022 - 01/2012
4	sodium sulfate (sodium bisulfate)FDA LinkGeneric 01/2022 - 12/2019
4	Lipoprotein Lipase (Diacylglycerol Lipase)IBA 01/2012 - 02/2005
4	PPAR gammaIBA 01/2012 - 02/2005
4	Prostaglandins EIBA 03/2007 - 01/2002
4	Prostaglandin E Receptors (Prostaglandin E Receptor)IBA 01/2006 - 01/2002
3	MutagensIBA 02/2023 - 01/2020
3	AntioxidantsIBA 01/2023 - 11/2019
3	Inosine Diphosphate (IDP)IBA 01/2023 - 01/2023
3	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2023 - 01/2005
3	CholesterolIBA 12/2022 - 04/2006
3	Cyclin D1IBA 03/2022 - 04/2017
3	Mesalamine (Mesalazine)FDA LinkGeneric 03/2022 - 01/2019
3	Dextrans (Dextran)FDA Link 01/2022 - 11/2020
3	Insulin (Novolin)FDA Link 07/2021 - 01/2012
3	Reactive Oxygen Species (Oxygen Radicals)IBA 01/2020 - 11/2015
3	LeptinIBA 01/2016 - 08/2011
3	Urethane (Ethyl Carbamate)IBA 08/2013 - 09/2008
3	Indomethacin (Indometacin)FDA LinkGeneric 11/2012 - 10/2007
3	4- diethoxyphosphorylmethyl- N- (4- bromo- 2- cyanophenyl)benzamideIBA 01/2012 - 02/2005
3	Pioglitazone (Actos)FDA Link 01/2012 - 04/2006
3	PPAR alphaIBA 10/2007 - 02/2005
2	Prostate-Specific Antigen (Semenogelase)IBA 12/2023 - 10/2023
2	Angiotensin Receptor AntagonistsIBA 12/2023 - 01/2016
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2023 - 03/2011
2	CytokinesIBA 01/2023 - 04/2017
2	Small Interfering RNA (siRNA)IBA 11/2022 - 12/2021
2	CC ChemokinesIBA 01/2022 - 12/2021
2	Peptides (Polypeptides)IBA 01/2022 - 01/2020
2	PolyketidesIBA 01/2022 - 01/2020
2	XanthophyllsIBA 01/2022 - 10/2017
2	Dietary CalciumIBA 07/2021 - 09/2013
2	SuspensionsIBA 01/2021 - 01/2019
2	Proliferating Cell Nuclear Antigen (PCNA)IBA 01/2020 - 07/2015
2	IntegrinsIBA 12/2019 - 08/2013
2	Transcription Factors (Transcription Factor)IBA 11/2019 - 08/2017
2	LuciferasesIBA 11/2019 - 08/2017
2	NF-kappa B (NF-kB)IBA 01/2019 - 10/2003
2	IsothiocyanatesIBA 01/2019 - 01/2017
2	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 08/2017 - 05/2017
2	TCF Transcription FactorsIBA 04/2017 - 07/2015
2	NADPH Oxidases (NAD(P)H oxidase)IBA 11/2015 - 03/2015
2	sesamolIBA 03/2015 - 03/2014
2	Plasminogen Activator Inhibitor 1IBA 01/2014 - 04/2008
2	AcidsIBA 08/2013 - 05/2012
2	cyclo(arginylglycyl)IBA 08/2013 - 05/2012
2	1,4,7,10-tetraazacyclododecane- 1,4,7,10-tetraacetic acidIBA 08/2013 - 05/2012
2	Plasminogen Activators (Plasminogen Activator)IBA 06/2011 - 04/2008
2	7- chloro- 3- imino- 5- methyl- 2- azabicyclo(4.1.0)heptaneIBA 08/2008 - 03/2006
2	HeptanesIBA 08/2008 - 03/2006
2	ONO 8711IBA 03/2007 - 05/2005

Therapy/Procedure

10	Chemoprevention 12/2022 - 01/2006
6	Colectomy 11/2023 - 01/2016
5	Therapeutics 01/2023 - 01/2005
2	Pancreaticoduodenectomy 10/2016 - 03/2014
2	Intraperitoneal Injections 08/2013 - 11/2012